Perioperative management of biologic agents in Crohn's disease

2022 ◽  
pp. 100865
Author(s):  
Valery Vilchez ◽  
Amy L. Lightner
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Perioperative Management ◽  
Biologic Agents

scholarly journals Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn’s Disease

2020 ◽  
Author(s):  
Mark T Osterman ◽  
Kelli L VanDussen ◽  
Ilyssa O Gordon ◽  
Elisabeth M Davis ◽  
Katherine Li ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Epithelial Cell ◽  
Crohn's Disease ◽  
Clinical Response ◽  
Predictive Value ◽  
Controlled Trial ◽  
Biologic Agents ◽  
Intestinal Epithelial ◽  
Randomized Controlled ◽  
Discriminant Ability

Abstract Background Therapeutic efficacy of biologics has remained at about 50% for 2 decades. In Crohn’s disease (CD) patients, we examined the predictive value of an epithelial cell biomarker, ileal microvillar length (MVL), for clinical response to ustekinumab (UST) and vedolizumab (VDZ) and its relationship to another biomarker, intestinal epithelial cell (IEC) pyroptosis, with respect to response to VDZ. Method Ileal biopsies from the UNITI-2 randomized controlled trial were analyzed for MVL as a predictor of clinical response to UST. In a 5-center academic retrospective cohort of CD patients, ileal MVL was analyzed to determine its predictive value for response to VDZ. Correlation between ileal MVL and IEC pyroptosis was determined, and the discriminant ability of the combination of 2 biomarkers to VDZ was examined. Results Clinical response in UST was significantly higher than placebo (65% vs 39%; P = 0.03), with patients with normal MVL (>1.7 µm) having the greatest therapeutic effect: 85% vs 20% (P = 0.02). For VDZ, clinical response with MVL of 1.35 to 1.55 µm was 82% vs 44% (<1.35 µm) and 40% (>1.55 µm; P = 0.038). There was no correlation between ileal MVL and IEC pyroptosis. The combination criteria of ileal pyroptosis <14 positive cells/1000 IECs or MVL of 1.35 to 1.55 µm could identify 84% of responders and 67% of nonresponders (P = 0.001). Conclusion Ileal MVL was predictive of response to UST and VDZ in prospective and retrospective CD cohorts. It was independent of ileal IEC pyroptosis, and combination of the 2 biomarkers enhanced the discriminate ability of responders from nonresponders to VDZ.

Su1133 Influence of Biologic Agents on Short-Term Postoperative Complications in Patients With Crohn's Disease: A Prospective, Single-Surgeon Cohort Study

2013 ◽  
Vol 144 (5) ◽  
pp. S-407 ◽  
Author(s):  
Cheryl C. Lau ◽  
Marla Dubinsky ◽  
Gil Y. Melmed ◽  
Eric A. Vasiliauskas ◽  
Dermot P. McGovern ◽  
...  
Keyword(s):  
Cohort Study ◽  
Crohn’S Disease ◽  
Postoperative Complications ◽  
Crohn's Disease ◽  
Biologic Agents ◽  
Short Term

scholarly journals Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

2019 ◽  
Vol 34 (8) ◽  
pp. 1296-1315 ◽  
Author(s):  
Choon Jin Ooi ◽  
Ida Hilmi ◽  
Rupa Banerjee ◽  
Sai Wei Chuah ◽  
Siew Chien Ng ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Best Practices ◽  
Biologic Agents

scholarly journals Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn’s disease: analysis from the PRACTICROHN study

2019 ◽  
Vol 7 (3) ◽  
pp. 168-175 ◽  
Author(s):  
Ana Gutiérrez ◽  
Montserrat Rivero ◽  
Maria Dolores Martín-Arranz ◽  
Valle García Sánchez ◽  
Manuel Castro ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Perioperative Management ◽  
Intestinal Resection ◽  
Early Complications ◽  
Ileocolonic Anastomosis ◽  
Disease Analysis

scholarly journals Cost Analysis of Certolizumab Pegol Compared With Available Biologic Agents For Crohn’s Disease In Mexico And Brazil

2015 ◽  
Vol 18 (7) ◽  
pp. A866
Author(s):  
A Aguirre ◽  
M Naranjo ◽  
H Bierschwale ◽  
M Treglia
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Cost Analysis ◽  
Certolizumab Pegol ◽  
Biologic Agents

scholarly journals Epithelial cell biomarkers are predictive of response to biologic agents in Crohn’s disease

2020 ◽  
Author(s):  
Mark T. Osterman ◽  
Kelli L. VanDussen ◽  
Ilyssa O. Gordon ◽  
Elisabeth M. Davis ◽  
Katherine Li ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Epithelial Cell ◽  
Crohn's Disease ◽  
Clinical Response ◽  
Predictive Value ◽  
Controlled Trial ◽  
Biologic Agents ◽  
Intestinal Epithelial ◽  
Randomized Controlled ◽  
Discriminant Ability

AbstractObjectiveTherapeutic efficacy of biologics has remained at about 50% for 2 decades. In Crohn’s disease (CD) patients, we examined the predictive value of an epithelial cell biomarker, ileal microvillar length (MVL), for clinical response to ustekinumab (UST) and vedolizumab (VDZ), and its relationship to another biomarker, intestinal epithelial cell (IEC) pyroptosis with respect to response to VDZ.DesignIleal biopsies from the UNITI-2 randomized controlled trial were analyzed for MVL as a predictor of clinical response to UST. In a 5-center academic retrospective cohort of CD patients, ileal MVL was analyzed to determine its predictive value for response to VDZ. Correlation between ileal MVL and IEC pyroptosis was determined, and the discriminant ability of the combination of two biomarkers to VDZ was examined.ResultsClinical response in UST was significantly higher than placebo (65% vs. 39%, p=0.03), with patients with normal MVL (>1.7 µm) having the greatest therapeutic effect: 85% vs. 20% (p=0.02). For VDZ, clinical response with MVL of 1.35-1.55 µm was 82% vs. 44% (<1.35 µm) and 40% (>1.55 µm) (p=0.038). There was no correlation between ileal MVL and IEC pyroptosis. The combination criteria of ileal pyroptosis < 14 positive cells/1000 IECs or MVL of 1.35-1.55 µm could identify 84% of responders and 67% of non-responders (p=0.001).ConclusionsIleal MVL was predictive of response to UST and VDZ in prospective and retrospective CD cohorts. It was independent of ileal IEC pyroptosis, combination of the two biomarkers enhanced the discriminate ability of responders from non-responders to VDZ.

scholarly journals S3315 Efficacy and Safety of Biologic Agents on Crohn’s Disease Elderly Patients: A Retrospective Analysis

2021 ◽  
Vol 116 (1) ◽  
pp. S1366-S1367
Author(s):  
Carlos J. Figueredo ◽  
Konstantin Boroda ◽  
Christopher Andrade ◽  
Tehseen Haider ◽  
Tamoor Shahid ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Elderly Patients ◽  
Retrospective Analysis ◽  
Biologic Agents ◽  
Efficacy And Safety

Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn’s Disease

2016 ◽  
Vol 50 (4) ◽  
pp. 326-330 ◽  
Author(s):  
William Ferges ◽  
Saroja Devi Rampertab ◽  
Muhammad Shafqet ◽  
Qasim Salimi ◽  
Geoffrey You ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Biologic Agents ◽  
Tnf Α
Sign in / Sign up

Export Citation Format

Share Document